Maximo Niguez
Chief Financial Officer
Replay available
Puma Biotechnology Inc (NASDAQ: PBYI) Q3 2025 earnings conference call, held 2025-11-06. Replay captured from the company's public earnings webcast.

Chief Financial Officer
Senior Vice President of Marketing
Chief Executive Officer, President and Chairman of the Board
Senior Vice President of Sales
Analyst, TD Cowen
Senior Director of Investor Relations
Good afternoon. My name is Julian and I'll be your conference call operator today. At this time, all participants are in a listen-only mode. After the speaker's formal remarks, there will be a question and answer session. If you'd like to ask a question during that time, simply press the star key, then the number one on your telephone keypad. If you'd like to withdraw your question, please press star two. If you should require operator assistance during the conference, please press star zero. As a reminder, this call is being recorded. I would now like to turn the conference call over to Marianne Ohanesian, Senior Director of IR for PUMA Biotechnology. Thank you. You may begin. Thank you, Julian. Good afternoon and welcome to PUMA's conference call to discuss our earnings results for the third quarter of 2025. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of PUMA Biotechnology, Maximo Niguez, Chief Financial Officer, Heather Blaber, Senior Vice President of Marketing, and Roger Storms, Senior Vice President of Sales. After the close today, PUMA issued a news release detailing earnings results for third quarter 2025. That news release, the slides that Roger will refer to, and a webcast of this call are accessible via the homepage and investor sections of our website at pumabiotechnology.com. The webcast and presentation slides will be archived on our website and available for replay for the next 90 days. Today's conference call will include statements about PUMA's future expectations, plans, and prospects that constitute forward-looking statements for purposes of federal securities laws. Such statements are subject to risks and uncertainties, and actual events and results may differ from those expressed in...